Home Events Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults

Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults

Date

April 07 2021

Time

1:00 pm - 2:30 pm

Speakers

  • Dr Gwyn Bebb
    Dr Gwyn Bebb

    Dr. Gwyn Bebb is a Medical Oncologist at the Tom Baker Cancer Centre (Calgary, AB) with a clinical focus in the treatment of lung malignancies. As Associate Professor of Medicine with The University of Calgary, he mentors graduate students, medical students, residents and other healthcare professionals.

  • Dr Ming Tsao
    Dr Ming Tsao

    Dr. Ming Tsao, FRCPC, MD
    Principal investigator
    Scientific Director, Princess Margaret Living Biobank
    Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
    Professor, Department of Medical Biophysics, University of Toronto

Description:

TRK fusions can occur in many types of pediatric and adult cancers. Two TRK inhibitors, larotrectinib and entrectinib recently have received Health Canada approval. Identifying patients whose tumours are driven by TRK fusion aberration can be challenging, as they may occur in low percentage of the respective patient populations. A multidisciplinary group of Canadian medical oncologists and pathologists were convened to develop the testing algorithm for identifying TRK fusion patients in 5 tumour types: lung, colorectal, thyroid, salivary gland and soft tissue cancers.

The presentation will discuss the consensus opinion of these experts on the biomarker testing algorithms for these tumours. At the end of this session participants will be able to:
Identify lung, colorectal, thyroid, salivary gland and soft tissue cancer patients who may harbour TRK fusion tumours
Understand the testing options to identify TRK fusion tumours

This content is restricted to subscribers


Register

Co-Developed with: